Rights statement: The final publication is available at Springer via http://dx.doi.org/10.1007/s40263-017-0451-y
Accepted author manuscript, 689 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease
AU - Li, Yanwei
AU - Zhao, Jinying
AU - Holscher, Christian
N1 - The final publication is available at Springer via http://dx.doi.org/10.1007/s40263-017-0451-y
PY - 2017/8
Y1 - 2017/8
N2 - Alzheimer's disease and Parkinson's disease are the two most common, progressive central neurodegenerative diseases affecting the population over the age of 60 years. Apart from treatments that temporarily improve symptoms, there is no medicine currently available to inhibit or reverse the progression of Alzheimer's disease and Parkinson's disease. In traditional Chinese medicine, the root of Scutellaria baicalensis Georgi is a classic compatible component in the decoction of herbal medicine used for treating central nervous system diseases. Modern pharmacokinetic studies have confirmed that baicalein (5,6,7-trihydroxyflavone) is a major bioactive flavone constituent root of S. baicalensis Georgi. Studies showed that baicalein possesses a range of key pharmacological properties, such as reducing oxidative stress, anti-inflammatory properties, inhibiting aggregation of diseasespecific amyloid proteins, inhibiting excitotoxicity, stimulating neurogenesis and differentiation action, and antiapoptosis effects. Based on these properties, baicalein shows therapeutic potential for Alzheimer's disease and Parkinson's disease. In this review, we summarize the pharmacological protective actions of baicalein that make it suitable for the treatment of Alzheimer's disease and Parkinson's disease, and discuss the potential mechanisms underlying the effects.
AB - Alzheimer's disease and Parkinson's disease are the two most common, progressive central neurodegenerative diseases affecting the population over the age of 60 years. Apart from treatments that temporarily improve symptoms, there is no medicine currently available to inhibit or reverse the progression of Alzheimer's disease and Parkinson's disease. In traditional Chinese medicine, the root of Scutellaria baicalensis Georgi is a classic compatible component in the decoction of herbal medicine used for treating central nervous system diseases. Modern pharmacokinetic studies have confirmed that baicalein (5,6,7-trihydroxyflavone) is a major bioactive flavone constituent root of S. baicalensis Georgi. Studies showed that baicalein possesses a range of key pharmacological properties, such as reducing oxidative stress, anti-inflammatory properties, inhibiting aggregation of diseasespecific amyloid proteins, inhibiting excitotoxicity, stimulating neurogenesis and differentiation action, and antiapoptosis effects. Based on these properties, baicalein shows therapeutic potential for Alzheimer's disease and Parkinson's disease. In this review, we summarize the pharmacological protective actions of baicalein that make it suitable for the treatment of Alzheimer's disease and Parkinson's disease, and discuss the potential mechanisms underlying the effects.
KW - AMYLOID OLIGOMERS IMPLIES
KW - BRAIN IRON ACCUMULATION
KW - NITRIC-OXIDE SYNTHASE
KW - ALPHA-SYNUCLEIN
KW - SCUTELLARIA-BAICALENSIS
KW - OXIDATIVE STRESS
KW - INDUCED NEUROTOXICITY
KW - IN-VITRO
KW - NEURODEGENERATIVE DISEASES
KW - DOPAMINERGIC-NEURONS
U2 - 10.1007/s40263-017-0451-y
DO - 10.1007/s40263-017-0451-y
M3 - Journal article
VL - 31
SP - 639
EP - 652
JO - CNS Drugs
JF - CNS Drugs
SN - 1172-7047
IS - 8
ER -